Gene Expression Signature Associated with Clinical Outcome in ALK-Positive Anaplastic Large Cell Lymphoma

Anaplastic large cell lymphomas associated with ALK translocation have a good outcome after CHOP treatment; however, the 2-year relapse rate remains at 30%. Microarray gene-expression profiling of 48 samples obtained at diagnosis was used to identify 47 genes that were differentially expressed betwe...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Daugrois Camille, Bessiere Chloé, Dejean Sébastien, Anton Leberre Véronique, Commes Thérèse, Stephane Pyronnet, Pierre Brousset, Estelle Espinos, Brugiere Laurence, Fabienne Meggetto, Laurence Lamant
Formato:	article
Lenguaje:	EN
Publicado:	MDPI AG 2021
Materias:	ALK<sup>+</sup> ALCL predictive signature relapse clinical outcome Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/664c157e324b4ccaac7c1d17057220bf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:664c157e324b4ccaac7c1d17057220bf
record_format	dspace
spelling	oai:doaj.org-article:664c157e324b4ccaac7c1d17057220bf2021-11-11T15:33:52ZGene Expression Signature Associated with Clinical Outcome in ALK-Positive Anaplastic Large Cell Lymphoma10.3390/cancers132155232072-6694https://doaj.org/article/664c157e324b4ccaac7c1d17057220bf2021-11-01T00:00:00Zhttps://www.mdpi.com/2072-6694/13/21/5523https://doaj.org/toc/2072-6694Anaplastic large cell lymphomas associated with ALK translocation have a good outcome after CHOP treatment; however, the 2-year relapse rate remains at 30%. Microarray gene-expression profiling of 48 samples obtained at diagnosis was used to identify 47 genes that were differentially expressed between patients with early relapse/progression and no relapse. In the relapsing group, the most significant overrepresented genes were related to the regulation of the immune response and T-cell activation while those in the non-relapsing group were involved in the extracellular matrix. Fluidigm technology gave concordant results for 29 genes, of which FN1, FAM179A, and SLC40A1 had the strongest predictive power after logistic regression and two classification algorithms. In parallel with 39 samples, we used a Kallisto/Sleuth pipeline to analyze RNA sequencing data and identified 20 genes common to the 28 genes validated by Fluidigm technology—notably, the <i>FAM179A</i> and <i>FN1</i> genes. Interestingly, FN1 also belongs to the gene signature predicting longer survival in diffuse large B-cell lymphomas treated with CHOP. Thus, our molecular signatures indicate that the FN1 gene, a matrix key regulator, might also be involved in the prognosis and the therapeutic response in anaplastic lymphomas.Daugrois CamilleBessiere ChloéDejean SébastienAnton Leberre VéroniqueCommes ThérèseStephane PyronnetPierre BroussetEstelle EspinosBrugiere LaurenceFabienne MeggettoLaurence LamantMDPI AGarticleALK<sup>+</sup> ALCLpredictive signaturerelapseclinical outcomeNeoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENCancers, Vol 13, Iss 5523, p 5523 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	ALK<sup>+</sup> ALCL predictive signature relapse clinical outcome Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	ALK<sup>+</sup> ALCL predictive signature relapse clinical outcome Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Daugrois Camille Bessiere Chloé Dejean Sébastien Anton Leberre Véronique Commes Thérèse Stephane Pyronnet Pierre Brousset Estelle Espinos Brugiere Laurence Fabienne Meggetto Laurence Lamant Gene Expression Signature Associated with Clinical Outcome in ALK-Positive Anaplastic Large Cell Lymphoma
description	Anaplastic large cell lymphomas associated with ALK translocation have a good outcome after CHOP treatment; however, the 2-year relapse rate remains at 30%. Microarray gene-expression profiling of 48 samples obtained at diagnosis was used to identify 47 genes that were differentially expressed between patients with early relapse/progression and no relapse. In the relapsing group, the most significant overrepresented genes were related to the regulation of the immune response and T-cell activation while those in the non-relapsing group were involved in the extracellular matrix. Fluidigm technology gave concordant results for 29 genes, of which FN1, FAM179A, and SLC40A1 had the strongest predictive power after logistic regression and two classification algorithms. In parallel with 39 samples, we used a Kallisto/Sleuth pipeline to analyze RNA sequencing data and identified 20 genes common to the 28 genes validated by Fluidigm technology—notably, the <i>FAM179A</i> and <i>FN1</i> genes. Interestingly, FN1 also belongs to the gene signature predicting longer survival in diffuse large B-cell lymphomas treated with CHOP. Thus, our molecular signatures indicate that the FN1 gene, a matrix key regulator, might also be involved in the prognosis and the therapeutic response in anaplastic lymphomas.
format	article
author	Daugrois Camille Bessiere Chloé Dejean Sébastien Anton Leberre Véronique Commes Thérèse Stephane Pyronnet Pierre Brousset Estelle Espinos Brugiere Laurence Fabienne Meggetto Laurence Lamant
author_facet	Daugrois Camille Bessiere Chloé Dejean Sébastien Anton Leberre Véronique Commes Thérèse Stephane Pyronnet Pierre Brousset Estelle Espinos Brugiere Laurence Fabienne Meggetto Laurence Lamant
author_sort	Daugrois Camille
title	Gene Expression Signature Associated with Clinical Outcome in ALK-Positive Anaplastic Large Cell Lymphoma
title_short	Gene Expression Signature Associated with Clinical Outcome in ALK-Positive Anaplastic Large Cell Lymphoma
title_full	Gene Expression Signature Associated with Clinical Outcome in ALK-Positive Anaplastic Large Cell Lymphoma
title_fullStr	Gene Expression Signature Associated with Clinical Outcome in ALK-Positive Anaplastic Large Cell Lymphoma
title_full_unstemmed	Gene Expression Signature Associated with Clinical Outcome in ALK-Positive Anaplastic Large Cell Lymphoma
title_sort	gene expression signature associated with clinical outcome in alk-positive anaplastic large cell lymphoma
publisher	MDPI AG
publishDate	2021
url	https://doaj.org/article/664c157e324b4ccaac7c1d17057220bf
work_keys_str_mv	AT daugroiscamille geneexpressionsignatureassociatedwithclinicaloutcomeinalkpositiveanaplasticlargecelllymphoma AT bessierechloe geneexpressionsignatureassociatedwithclinicaloutcomeinalkpositiveanaplasticlargecelllymphoma AT dejeansebastien geneexpressionsignatureassociatedwithclinicaloutcomeinalkpositiveanaplasticlargecelllymphoma AT antonleberreveronique geneexpressionsignatureassociatedwithclinicaloutcomeinalkpositiveanaplasticlargecelllymphoma AT commestherese geneexpressionsignatureassociatedwithclinicaloutcomeinalkpositiveanaplasticlargecelllymphoma AT stephanepyronnet geneexpressionsignatureassociatedwithclinicaloutcomeinalkpositiveanaplasticlargecelllymphoma AT pierrebrousset geneexpressionsignatureassociatedwithclinicaloutcomeinalkpositiveanaplasticlargecelllymphoma AT estelleespinos geneexpressionsignatureassociatedwithclinicaloutcomeinalkpositiveanaplasticlargecelllymphoma AT brugierelaurence geneexpressionsignatureassociatedwithclinicaloutcomeinalkpositiveanaplasticlargecelllymphoma AT fabiennemeggetto geneexpressionsignatureassociatedwithclinicaloutcomeinalkpositiveanaplasticlargecelllymphoma AT laurencelamant geneexpressionsignatureassociatedwithclinicaloutcomeinalkpositiveanaplasticlargecelllymphoma
_version_	1718435182414921728

Gene Expression Signature Associated with Clinical Outcome in ALK-Positive Anaplastic Large Cell Lymphoma

Ejemplares similares